Patents by Inventor Kengo Noguchi
Kengo Noguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11923320Abstract: A semiconductor device includes a semiconductor die having a top side surface comprising a semiconductor material including circuitry therein having bond pads connected to nodes in the circuitry, a bottom side surface, and sidewall surfaces between the top side surface and the bottom side surface. A metal coating layer including a bottom side metal layer is over the bottom side surface that extends continuously to a sidewall metal layer on the sidewall surfaces. The sidewall metal layer defines a sidewall plane that is at an angle from 10° to 60° relative to a normal projected from a bottom plane defined by the bottom side metal layer.Type: GrantFiled: December 31, 2020Date of Patent: March 5, 2024Assignee: TEXAS INSTRUMENTS INCORPORATEDInventors: Tomoko Noguchi, Mutsumi Masumoto, Kengo Aoya, Masamitsu Matsuura
-
Patent number: 10525664Abstract: Provided is an air-permeable sheet (3) to be used in a state of being interposed between a suction stage (1) and an air-impermeable substrate (4) when printing is performed by a sheet-fed method on the surface of the substrate (4) fixed by suction to the suction stage (1), the air-permeable sheet capable of printing a desired printing pattern on the surface of the substrate with high accuracy. The air-permeable sheet (3) includes a non-woven fabric layer (3b) and a support layer (3a) constituted by a woven fabric or knitted fabric.Type: GrantFiled: April 17, 2015Date of Patent: January 7, 2020Assignees: JAPAN VILENE COMPANY, LTD., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Kenichi Nomura, Hirobumi Ushijima, Kengo Noguchi, Noriko Michihata, Takeshi Kobayashi, Masaaki Kawabe
-
Patent number: 10517850Abstract: The present invention provides a pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a particular TAFIa inhibitor and a plasminogen activator, the TAFIa inhibitor being administered in combination with the plasminogen activator, and a method for treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a particular TAFIa inhibitor in combination with a plasminogen activator to a warm-blooded animal.Type: GrantFiled: June 16, 2016Date of Patent: December 31, 2019Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kengo Noguchi, Yusuke Ito, Naoko Edo
-
Publication number: 20190117624Abstract: A therapeutic agent for inflammatory bowel diseases comprising as an active ingredient a compound represented by the formula (I) wherein R represents a hydrogen atom or a [1-(isobutyryloxy)ethoxy]carbonyl group or the like, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: March 28, 2017Publication date: April 25, 2019Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kengo NOGUCHI, Yusuke ITO
-
Publication number: 20180315554Abstract: The object of the present invention is to realize a separator that has excellent thermal stability in size, shape, and the like even in a high temperature environment. The separator comprises a nonwoven fabric obtained by subjecting a nonwoven fabric consisting of homo-PAN fibers to a flame proofing treatment in a temperature range of 210° C. to 300° C., wherein an ID/IN value, which is a ratio of an absorption peak intensity ID of a carbon double bond-derived region (1580-1610 cm?1) of the homo-PAN nonwoven fabric to an absorption peak intensity IN derived from a nitrile group (2240 cm?1), as determined by infrared absorption spectroscopy, is 0.07 or more; and wherein a fiber shape and size are stably maintained after immersion for 30 minutes in an electrolytic solution containing propylene carbonate at 140° C.Type: ApplicationFiled: November 4, 2016Publication date: November 1, 2018Applicant: JAPAN VILENE COMPANY, LTD.Inventors: Kengo NOGUCHI, Noriko MICHIHATA, Yoshinori SATO
-
Publication number: 20180243268Abstract: The present invention provides a pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a particular TAFIa inhibitor and a plasminogen activator, the TAFIa inhibitor being administered in combination with the plasminogen activator, and a method for treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a particular TAFIa inhibitor in combination with a plasminogen activator to a warm-blooded animal.Type: ApplicationFiled: June 16, 2016Publication date: August 30, 2018Inventors: Kengo NOGUCHI, Yusuke ITO, Naoko EDO
-
Publication number: 20170232705Abstract: Provided is an air-permeable sheet (3) to be used in a state of being interposed between a suction stage (1) and an air-impermeable substrate (4) when printing is performed by a sheet-fed method on the surface of the substrate (4) fixed by suction to the suction stage (1), the air-permeable sheet capable of printing a desired printing pattern on the surface of the substrate with high accuracy. The air-permeable sheet (3) includes a non-woven fabric layer (3b) and a support layer (3a) constituted by a woven fabric or knitted fabric.Type: ApplicationFiled: April 17, 2015Publication date: August 17, 2017Applicants: Japan Vilene Company, Ltd., National Institute of Advanced Industrial Science and TechnologyInventors: Kenichi NOMURA, Hirobumi USHIJIMA, Kengo NOGUCHI, Noriko MICHIHATA, Takeshi KOBAYASHI, Masaaki KAWABE
-
Patent number: 9662310Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: GrantFiled: February 3, 2015Date of Patent: May 30, 2017Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi
-
Patent number: 9340531Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.Type: GrantFiled: December 16, 2013Date of Patent: May 17, 2016Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
-
Publication number: 20150216847Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: ApplicationFiled: February 3, 2015Publication date: August 6, 2015Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu NAGATA, Jun KOBAYASHI, Yoshiyuki ONISHI, Masamichi KISHIDA, Kengo NOGUCHI
-
Patent number: 9037003Abstract: A signal transmission device drives a light-emitting element and outputs an optical signal depending on a data signal from an electronic device. The device includes an element driving portion which supplies a driving current to the light-emitting element, wherein the driving current is obtained by superimposing a modulation current on a bias current, the modulation current being dependent on the data signal indicating emitting information of the light-emitting element. A temperature compensation portion of the device controls the bias current and the modulation current depending on the temperature so that a temperature-current characteristic of the light-emitting element is reproduced based on the voltage which is dependent on the temperature and the voltage which is independent from the temperature, thereby performing current control depending on the temperature.Type: GrantFiled: March 26, 2013Date of Patent: May 19, 2015Assignee: YAZAKI CORPORATIONInventors: Chiemi Yamagata, Atsushi Nakata, Kengo Noguchi, Yukio Akazawa
-
Patent number: 8946443Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: GrantFiled: March 14, 2011Date of Patent: February 3, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi
-
Publication number: 20140178349Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.Type: ApplicationFiled: December 16, 2013Publication date: June 26, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
-
Patent number: 8609710Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.Type: GrantFiled: July 16, 2012Date of Patent: December 17, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
-
Publication number: 20130230501Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.Type: ApplicationFiled: July 16, 2012Publication date: September 5, 2013Applicant: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
-
Publication number: 20130022587Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents —CH2—CHR5—CH2—NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.Type: ApplicationFiled: July 16, 2012Publication date: January 24, 2013Applicant: Daiichi Sankyo Company, LimitedInventors: Tsutomu Nagata, Masahiro Inoue, Yuka Ashida, Kengo Noguchi, Makoto Ono
-
Publication number: 20130012532Abstract: A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a C1 to C6 alkyl group which may be substituted by one to three groups selected from substituent group A, or the like (substituent group A: a hydroxy group, a halogeno group, a cyano group, a nitro group, an amino group, a carboxy group, a C1 to C3 alkyl group, etc.); R2, R3, and R8 each independently represent a hydrogen atom or a C1 to C3 alkyl group; R4, R5, R6, R7, R9, and R10 each independently represent a hydrogen atom or the like; and R11 represents a hydrogen atom or the like, has TAFIa enzyme inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, or the like.Type: ApplicationFiled: March 14, 2011Publication date: January 10, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsutomu Nagata, Jun Kobayashi, Yoshiyuki Onishi, Masamichi Kishida, Kengo Noguchi